Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20901800 | 0.86 | HRH3 (0.65) | ALDH1A1LMNAPOLBCXCR4HRH3 | |
| SCHEMBL10199478 | 0.82 | SIGMAR1 (0.55) | ALDH1A1LMNAPOLBHRH3 | |
| SCHEMBL21983550 | 0.82 | ALDH1A1 (0.47) | ALDH1A1LMNAPOLBHRH3 | |
| SCHEMBL13215736 | 0.79 | ALDH1A1 (0.70) | ALDH1A1LMNAPOLBCXCR4HRH3 | |
| SCHEMBL1046331 | 0.79 | ALDH1A1 (0.70) | ALDH1A1LMNAPOLBCXCR4HRH3 | |
| SCHEMBL11852 | 0.79 | HRH3 (0.74) | ALDH1A1LMNAPOLBCXCR4HRH3 | |
| SCHEMBL11864 | 0.78 | HRH3 (0.71) | ALDH1A1LMNAPOLBHRH3KMT2A | |
| SCHEMBL329323 | 0.77 | HRH3 (0.78) | ALDH1A1LMNAPOLBCXCR4HRH3 | |
| SCHEMBL1045595 | 0.77 | ALDH1A1 (0.74) | ALDH1A1LMNAPOLBCXCR4HRH3 | |
| SCHEMBL1045984 | 0.77 | ALDH1A1 (0.74) | ALDH1A1LMNAPOLBCXCR4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2019-03-28 | — | — | US | disclosed |
| US-20160032038-A1 | POLYMERIC IONIC SALT CATALYSTS AND METHODS OF PRODUCING THEREOF | MIDORI USA, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092779-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | ALDH1A1 367/4885LMNA 2970/4885POLB 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.